XML 58 R46.htm IDEA: XBRL DOCUMENT
v3.22.2

Equity Method and Other Equity Investments - Additional Information (Detail) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Oct. 31, 2019 USD ($) Director shares | Dec. 31, 2021 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Nov. 01, 2021 | Mar. 31, 2021 USD ($)
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |  |  |  |
Fair value of warrants |  | $ 2,100,000 |  |  | $ 800,000 |  | $ 2,100,000 |  |  |
Equity security investment |  | 49,148,000 | [1] |  | 27,141,000 |  | 49,148,000 | [1] |  |
LEO call option liability |  |  |  |  |  |  |  |  |  | $ 0
LianBio |  |  |  |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |  |  |  |
Equity security investment |  | 30,800,000 |  |  | 10,800,000 |  | 30,800,000 |  |  |
LianBio | Equity Method Investee's IPO |  |  |  |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |  |  |  |
Ownership interest |  |  |  |  |  |  |  |  | 4.70% |
Gain on conversion from equity method investment to investment in equity securities |  | $ 68,500,000 |  |  |  |  |  |  |  |
Unrealized loss on ongoing mark-to-market adjustments of investment in equity security |  |  |  |  | $ 57,700,000 |  | $ 37,700,000 |  |  |
Bridge Bio Pharma Limited Liability Company | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd | LianBio |  |  |  |  |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |  |  |  |  |
Ownership interest | 10.00% |  |  |  |  |  |  |  |  |
Number of directors appoint or removal | Director | 1 |  |  |  |  |  |  |  |  |
Ownership interest, value | $ 3,800,000 |  |  |  |  |  |  |  |  |
Impairments related investment |  |  |  | $ 0 |  | $ 0 |  |  |  |
Warrant to purchase percentage | 10.00% |  |  |  |  |  |  |  |  |
Warrants to purchase common stock | shares | 347,569 |  |  |  |  |  |  |  |  |
[1] | The condensed consolidated balance sheet as of December 31, 2021 is derived from the audited consolidated financial statements as of that date.

X
- Definition Gain from conversion of equity method investment to investment in equity securities. + References No definition available. + Details
Name: | bbio_GainFromConversionOfEquityMethodInvestmentToInvestmentInEquitySecurities
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition LEO call option liability current. + References No definition available. + Details
Name: | bbio_LEOCallOptionLiabilityCurrent
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of directors appoint or removal + References No definition available. + Details
Name: | bbio_NumberOfDirectorsAppointOrRemoval
Namespace Prefix: | bbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Warrant to purchase percentage. + References No definition available. + Details
Name: | bbio_WarrantToPurchasePercentage
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrant to purchase shares of common stock + References No definition available. + Details
Name: | bbio_WarrantToPurchaseSharesOfCommonStock
Namespace Prefix: | bbio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties. + References No definition available. + Details
Name: | us-gaap_EquityFairValueAdjustment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 45 -Paragraph 1A -URI https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740 + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 8A -URI https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562 + Details
Name: | us-gaap_ImpairmentOfInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of warrants not settleable in cash classified as equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_WarrantsNotSettleableInCashFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bbio_LianBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=bbio_EquityMethodInvesteesIpoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bbio_BridgeBioPharmaLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bbio_EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |